Newly Approved Immunotherapies for Adult Precursor B-acute Lymphoblastic Leukemia

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2017, vol. 7, issue 1, 5-8

Abstract: Most adults with B-cell precursor ALL will relapse and will die from complications of resistant disease or associated treatment. A major goal in B-cell precursor ALL is to induce remission of sufficient duration to prepare for stem-cell transplantation. The US FDA has recently approved three immunotherapies for this disease. CAR-T therapy, for the treatment of patients up to 25 years of age with B cell precursor ALL that is refractory or in second or later relapse, INO for the treatment of adults with R/R CD22 positive precursor B ALL and blinatumomab for treatment of precursor B ALL in adult and pediatric population.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555702.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555702.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:7:y:2017:i:1:p:5-8

DOI: 10.19080/CTOIJ.2017.07.555702

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().